Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

by Fredriksson, Martin , Langkilde, Anna-Maria , Sabatine, Marc S , Bhatt, Deepak L , Johansson, Peter A , Mosenzon, Ofri , Wilding, John P.H , Ruff, Christian T , Raz, Itamar , Kuder, Julia F , Kato, Eri T , Zelniker, Thomas A , Leiter, Lawrence A , Murphy, Sabina A , McGuire, Darren K , Bonaca, Marc P , Gause-Nilsson, Ingrid A.M , Wiviott, Stephen D , Cahn, Avivit , Silverman, Michael G

in adverse effects / Aged / Animal biology / Antidiabetics / Arteriosclerosis / Benzhydryl Compounds / Benzhydryl Compounds - adverse effects / Benzhydryl Compounds - therapeutic use / Cardiovascular disease / Cardiovascular Diseases / Cardiovascular Diseases - etiology / Cardiovascular Diseases - mortality / Cardiovascular Diseases - prevention & control / Cellular Biology / Cerebral infarction / Clinical Medicine / complications / Congestive heart failure / Death / Diabetes / Diabetes Mellitus / Diabetes mellitus (non-insulin dependent) / Diabetes Mellitus, Type 2 - complications / Diabetes Mellitus, Type 2 - drug therapy / Diabetic ketoacidosis / Drug therapy / End-stage renal disease / epidemiology / etiology / FDA approval / Female / Food and Nutrition / Glomerular filtration rate / Glucosides / Glucosides - adverse effects / Glucosides - therapeutic use / Heart attacks / Heart Failure / Heart Failure - epidemiology / Heart rate / Hospitalization / Hospitalization - statistics & numerical data / Humans / Ischemia / Ketoacidosis / Kidney diseases / Klinisk medicin / Life Sciences / Male / Middle Aged / Mortality / Myocardial infarction / Patients / Pharmaceutical sciences / prevention & control / Safety / Sodium / Sodium-glucose cotransporter / Sodium-Glucose Transporter 2 Inhibitors / Sodium-Glucose Transporter 2 Inhibitors - adverse effects / Sodium-Glucose Transporter 2 Inhibitors - therapeutic use / statistics & numerical data / therapeutic use / Type 2

2019

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

2019

Confirm

Do you wish to request the book?

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

2019

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Fredriksson, Martin,

Langkilde, Anna-Maria,

Sabatine, Marc S,

Bhatt, Deepak L,

Johansson, Peter A,

Mosenzon, Ofri,

Wilding, John P.H,

Ruff, Christian T,

Raz, Itamar,

Kuder, Julia F,

Kato, Eri T,

Zelniker, Thomas A,

Leiter, Lawrence A,

Murphy, Sabina A,

McGuire, Darren K,

Bonaca, Marc P,

Gause-Nilsson, Ingrid A.M,

Wiviott, Stephen D,

Cahn, Avivit,

Silverman, Michael G

2019

Overview

In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher or lower rate of cardiovascular death, myocardial infarction, or stroke than placebo but did result in a lower rate of hospitalization for heart failure.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

/ Aged

/ Benzhydryl Compounds

/ Benzhydryl Compounds - adverse effects